Second-line FOLFOX chemotherapy for advanced biliary tract cancer - Authors' reply.
Abstract
No abstract available
Author
Lamarca, Angela
Palmer, Daniel H
Wasan, Harpreet Singh
Ross, Paul J
Ma, Yuk Ting
Arora, Arvind
Falk, Stephen
Gillmore, Roopinder
Wadsley, Jonathan
Patel, Kinnari
Anthoney, Alan
Maraveyas, Anthony
Iveson, Tim
Waters, Justin S
Hobbs, Claire
Barber, Safia
Ryder, W David
Ramage, John
Davies, Linda M
Bridgewater, John A
Valle, Juan W
Palmer, Daniel H
Wasan, Harpreet Singh
Ross, Paul J
Ma, Yuk Ting
Arora, Arvind
Falk, Stephen
Gillmore, Roopinder
Wadsley, Jonathan
Patel, Kinnari
Anthoney, Alan
Maraveyas, Anthony
Iveson, Tim
Waters, Justin S
Hobbs, Claire
Barber, Safia
Ryder, W David
Ramage, John
Davies, Linda M
Bridgewater, John A
Valle, Juan W
Citations
Altmetric:
Date
2021-07
Type
Other
Subject
Haematology
Collections
Citation
Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, Arora A, Falk S, Gillmore R, Wadsley J, Patel K, Anthoney A, Maraveyas A, Iveson T, Waters JS, Hobbs C, Barber S, Ryder WD, Ramage J, Davies LM, Bridgewater JA, Valle JW; Advanced Biliary Cancer Working Group. Second-line FOLFOX chemotherapy for advanced biliary tract cancer - Authors' reply. Lancet Oncol. 2021 Jul;22(7):e288-e289. doi: 10.1016/S1470-2045(21)00341-7
Journal / Source Title
The Lancet Oncology
DOI
10.1016/S1470-2045(21)00341-7
PMID
34197751
Publisher
Elsevier
Publisher’s URL
http://www.sciencedirect.com/science/journal/14702045